|
|
Post by mnholdem on Jul 13, 2015 9:36:56 GMT -5
From Sanofi's July 7 Pre-quarterly (2Q15) Results Communication:
Number of Shares - The average number of shares for EPS calculation was 1,305.9 million in Q2 2015.
Share Buyback - In Q2 2015, Sanofi bought back 4.68 million shares totaling €448 million. In H1 2015, Sanofi repurchased 13.9
million shares totaling €1.24 billion.
en.sanofi.com/investors/events/corporate/2015/2015-07-30_Results_Q2_2015.aspx
[I corrected the date in the subject line.
-BD] |
|
|
|
Post by centralcoastinvestor on Jul 13, 2015 9:48:05 GMT -5
From Sanofi's July 7 Pre-quarterly (2Q15) Results Communication:
Number of Shares - The average number of shares for EPS calculation was 1,305.9 million in Q2 2015.
Share Buyback - In Q2 2015, Sanofi bought back 4.68 million shares totaling €448 million. In H1 2015, Sanofi repurchased 13.9
million shares totaling €1.24 billion.
en.sanofi.com/investors/events/corporate/2015/2015-07-30_Results_Q2_2015.aspx Good Morning, the Sanofi IR IPad App shows the next earnings to be reported July 30. Is there a discrepancy somewhere? |
|
|
|
Post by ezrasfund on Jul 13, 2015 9:50:16 GMT -5
Earnings report after the close 7/30; Conference call the next morning 7/31?
|
|
|
|
Post by newmnkdinvestor on Jul 13, 2015 11:12:28 GMT -5
What are some of you expecting?
|
|
|
|
Post by centralcoastinvestor on Jul 13, 2015 12:44:51 GMT -5
What are some of you expecting? I know many are counting on some dramatic good news to break the lock that shorts have on this stock. However, I'm leaning towards some bland announcement on Afrezza sales projections from Sanofi at a quarterly meeting to be just what the doctor ordered. I'm not sure Sanofi will be ready to do that on July 30, but maybe. |
|
|
|
Post by mnholdem on Jul 13, 2015 12:45:43 GMT -5
I'll be expecting actual Afrezza sales to eclipse IMS/Symphony scripts reports. Will it be by a factor of two once again?
|
|
|
|
Post by stevil on Jul 13, 2015 12:48:25 GMT -5
I'm new to biotech stocks.
From what I've gathered, MNKD doesn't follow the trend anyway.
How would earnings impact us since so much of it is future speculation? Is there such thing as a "bad" earnings report, assuming sales keep increasing? Who determines whether sales have missed or not? Is there a number out there to anyone's knowledge?
|
|
|
|
Post by newmnkdinvestor on Jul 13, 2015 13:56:45 GMT -5
What are some of you expecting? I know many are counting on some dramatic good news to break the lock that shorts have on this stock. However, I'm leaning towards some bland announcement on Afrezza sales projections from Sanofi at a quarterly meeting to be just what the doctor ordered. I'm not sure Sanofi will be ready to do that on July 30, but maybe. That's what I was thinking. The correlation in stock price to 1st quarter earnings were starting to look very similar until the past two days. This stock really beats to its own drum. I thought for sure with scripts down Friday it would have impacted the price. Does this Diabtes author from Twitter have that much juice to re assure some people into buying this AM? |
|
|
|
Post by newmnkdinvestor on Jul 13, 2015 13:59:13 GMT -5
I'm new to biotech stocks. From what I've gathered, MNKD doesn't follow the trend anyway. How would earnings impact us since so much of it is future speculation? Is there such thing as a "bad" earnings report, assuming sales keep increasing? Who determines whether sales have missed or not? Is there a number out there to anyone's knowledge? MNKD was slaughtered when SNY reported and then slaughtered again when MNKD reported. I thought we were starting to look at a similar event but these past two days have thrown me off. |
|
